Drug company Ipsen has unveiled a 4.6% rise in annual profits to 150.6m euro.
The increase on the 144m euro recorded in 2006 reflects a 5.1% rise in revenue to 993.8m euro, compared with 945.3m euro posted the year before.
Ipsen revealed it has also received three positive opinions for new drug indications in the US and EU in the last seven months.
President Jean-Luc Belingard said: “The group’s performance in 2007 is in line with our objectives despite a difficult environment marked by sustained price pressure and increased competition, notably in France.
“This set of results shows once again Ipsen’s ability to generate a strong and recurring cash flow.
“We will use our solid balance sheet as a tool to accelerate Ipsen’s growth going forward.”
He added: “In the framework of our strategy, we have further optimised our primary care franchise after the sale of Ginkor Fort, with the launch of Adrovance in France and the recent positive CHMP opinion for Adenuric (febuxostat) in Europe.
“Furthermore, upon marketing approval by the European Commission, Adenuric will stand out as a major therapeutic innovation in a pathology for which none has emerged during the past 40 years, thereby illustrating Ipsen’s mission to propose treatments for high unmet medical needs.”
Copyright Â© PA Business 2008